,NU636/NU 636 Advanced Pharmacology
Quiz 3 Bundle | Herzing | 26/27
Actual(PDF)
1. A 72-year-old patient with a history of heart failure and a creatinine clearance of 28 mL/min is
prescribed a medication that is primarily eliminated by the kidneys. Which pharmacokinetic
parameter will most significantly alter the dosing regimen for this patient?
A) Volume of distribution
B) Bioavailability
C) Renal clearance
D) Protein binding
Correct Answer: Renal clearance
Rationale: Renal clearance is the primary pharmacokinetic parameter that determines the elimination
of drugs excreted unchanged by the kidneys. In a patient with a creatinine clearance of 28 mL/min,
which indicates moderate to severe renal impairment, the kidneys' ability to filter and excrete the
drug is significantly reduced. This leads to drug accumulation, a prolonged half-life, and an increased
risk of toxicity. Dose adjustment, such as reducing the dose or extending the dosing interval, is
essential. While volume of distribution and protein binding can be altered in renal disease, renal
clearance is the most direct and critical parameter for drugs that are renally eliminated. Bioavailability
refers to the extent and rate at which the active drug enters systemic circulation, which is primarily
affected by the route of administration and first-pass metabolism, not by renal function.
2. A patient is started on a medication that is a potent inhibitor of the cytochrome P450 3A4
isoenzyme. Which clinical consequence should the nurse anticipate?
A) Decreased therapeutic effect of drugs metabolized by CYP3A4
B) Increased plasma concentration of drugs metabolized by CYP3A4
C) No significant interaction with other medications
D) Increased renal excretion of drugs metabolized by CYP3A4
,Correct Answer: Increased plasma concentration of drugs metabolized by CYP3A4
Rationale: Cytochrome P450 3A4 is responsible for the metabolism of a vast array of drugs, including
many statins, benzodiazepines, and calcium channel blockers. When a potent inhibitor, such as
ketoconazole or ritonavir, is co-administered, it reduces the metabolic clearance of drugs that are
substrates of CYP3A4. This inhibition leads to increased plasma concentrations of the substrate drug,
prolonging its effects and significantly elevating the risk of dose-related adverse effects or toxicity. For
example, combining a CYP3A4 inhibitor with a statin can increase the risk of myopathy and
rhabdomyolysis. Enzyme inducers would have the opposite effect, decreasing plasma concentrations.
Renal excretion is generally not the primary route of elimination for CYP3A4 substrates.
3. A patient with asthma is prescribed a short-acting beta-2 agonist for acute bronchospasm. The
nurse understands that the therapeutic effect of this medication is achieved through which
mechanism?
A) Inhibition of leukotriene synthesis
B) Blockade of muscarinic receptors
C) Stimulation of beta-2 adrenergic receptors
D) Inhibition of phosphodiesterase enzymes
Correct Answer: Stimulation of beta-2 adrenergic receptors
Rationale: Short-acting beta-2 agonists, such as albuterol, produce bronchodilation by selectively
stimulating beta-2 adrenergic receptors located on bronchial smooth muscle. This stimulation
activates intracellular signaling cascades that lead to smooth muscle relaxation and rapid opening of
the airways, providing prompt relief from acute bronchospasm. Leukotriene synthesis inhibitors (e.g.,
zileuton) and leukotriene receptor antagonists (e.g., montelukast) are used for chronic asthma
management. Muscarinic receptor antagonists, such as ipratropium, also cause bronchodilation but
through a different mechanism. Phosphodiesterase inhibitors, such as theophylline, have a narrower
therapeutic index and are not first-line for acute relief.
4. A patient is prescribed warfarin for the prevention of thromboembolism. Which instruction should
the nurse include regarding dietary vitamin K intake?
, A) "You should avoid all foods rich in vitamin K."
B) "You should maintain a consistent intake of vitamin K-rich foods."
C) "You should increase your intake of vitamin K-rich foods to prevent bleeding."
D) "Your vitamin K intake does not affect your warfarin therapy."
Correct Answer: "You should maintain a consistent intake of vitamin K-rich foods."
Rationale: Warfarin is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent
clotting factors (II, VII, IX, and X). Its anticoagulant effect is monitored using the international
normalized ratio (INR). Fluctuations in dietary vitamin K intake can significantly alter the INR, leading
to either an increased risk of bleeding (if intake is decreased) or a loss of anticoagulant effect (if intake
is increased). Patients should be counseled to maintain a consistent daily intake of vitamin K-rich
foods, such as leafy green vegetables, rather than eliminating them entirely. Consistency is crucial for
stable anticoagulation. Avoiding vitamin K entirely could lead to an unstable INR and is not a
sustainable or safe long-term strategy.
5. A patient with type 2 diabetes mellitus is prescribed metformin. Which statement accurately
describes the primary mechanism of action of this medication?
A) It increases insulin secretion from pancreatic beta cells.
B) It decreases hepatic glucose production and improves insulin sensitivity.
C) It increases glucose absorption in the intestines.
D) It inhibits glucagon release from pancreatic alpha cells.
Correct Answer: It decreases hepatic glucose production and improves insulin sensitivity.
Rationale: Metformin is the first-line pharmacologic therapy for type 2 diabetes. Its primary
mechanism of action involves decreasing hepatic glucose production (gluconeogenesis) and improving
peripheral insulin sensitivity, which enhances glucose uptake by skeletal muscle and adipose tissue. It
does not directly stimulate insulin secretion, which is the mechanism of sulfonylureas and
meglitinides. It does not increase glucose absorption; in fact, it may decrease intestinal glucose
absorption. While it may have some effect on glucagon, this is not its primary mechanism.
Understanding this mechanism is essential for patient education and monitoring therapeutic
outcomes.
Quiz 3 Bundle | Herzing | 26/27
Actual(PDF)
1. A 72-year-old patient with a history of heart failure and a creatinine clearance of 28 mL/min is
prescribed a medication that is primarily eliminated by the kidneys. Which pharmacokinetic
parameter will most significantly alter the dosing regimen for this patient?
A) Volume of distribution
B) Bioavailability
C) Renal clearance
D) Protein binding
Correct Answer: Renal clearance
Rationale: Renal clearance is the primary pharmacokinetic parameter that determines the elimination
of drugs excreted unchanged by the kidneys. In a patient with a creatinine clearance of 28 mL/min,
which indicates moderate to severe renal impairment, the kidneys' ability to filter and excrete the
drug is significantly reduced. This leads to drug accumulation, a prolonged half-life, and an increased
risk of toxicity. Dose adjustment, such as reducing the dose or extending the dosing interval, is
essential. While volume of distribution and protein binding can be altered in renal disease, renal
clearance is the most direct and critical parameter for drugs that are renally eliminated. Bioavailability
refers to the extent and rate at which the active drug enters systemic circulation, which is primarily
affected by the route of administration and first-pass metabolism, not by renal function.
2. A patient is started on a medication that is a potent inhibitor of the cytochrome P450 3A4
isoenzyme. Which clinical consequence should the nurse anticipate?
A) Decreased therapeutic effect of drugs metabolized by CYP3A4
B) Increased plasma concentration of drugs metabolized by CYP3A4
C) No significant interaction with other medications
D) Increased renal excretion of drugs metabolized by CYP3A4
,Correct Answer: Increased plasma concentration of drugs metabolized by CYP3A4
Rationale: Cytochrome P450 3A4 is responsible for the metabolism of a vast array of drugs, including
many statins, benzodiazepines, and calcium channel blockers. When a potent inhibitor, such as
ketoconazole or ritonavir, is co-administered, it reduces the metabolic clearance of drugs that are
substrates of CYP3A4. This inhibition leads to increased plasma concentrations of the substrate drug,
prolonging its effects and significantly elevating the risk of dose-related adverse effects or toxicity. For
example, combining a CYP3A4 inhibitor with a statin can increase the risk of myopathy and
rhabdomyolysis. Enzyme inducers would have the opposite effect, decreasing plasma concentrations.
Renal excretion is generally not the primary route of elimination for CYP3A4 substrates.
3. A patient with asthma is prescribed a short-acting beta-2 agonist for acute bronchospasm. The
nurse understands that the therapeutic effect of this medication is achieved through which
mechanism?
A) Inhibition of leukotriene synthesis
B) Blockade of muscarinic receptors
C) Stimulation of beta-2 adrenergic receptors
D) Inhibition of phosphodiesterase enzymes
Correct Answer: Stimulation of beta-2 adrenergic receptors
Rationale: Short-acting beta-2 agonists, such as albuterol, produce bronchodilation by selectively
stimulating beta-2 adrenergic receptors located on bronchial smooth muscle. This stimulation
activates intracellular signaling cascades that lead to smooth muscle relaxation and rapid opening of
the airways, providing prompt relief from acute bronchospasm. Leukotriene synthesis inhibitors (e.g.,
zileuton) and leukotriene receptor antagonists (e.g., montelukast) are used for chronic asthma
management. Muscarinic receptor antagonists, such as ipratropium, also cause bronchodilation but
through a different mechanism. Phosphodiesterase inhibitors, such as theophylline, have a narrower
therapeutic index and are not first-line for acute relief.
4. A patient is prescribed warfarin for the prevention of thromboembolism. Which instruction should
the nurse include regarding dietary vitamin K intake?
, A) "You should avoid all foods rich in vitamin K."
B) "You should maintain a consistent intake of vitamin K-rich foods."
C) "You should increase your intake of vitamin K-rich foods to prevent bleeding."
D) "Your vitamin K intake does not affect your warfarin therapy."
Correct Answer: "You should maintain a consistent intake of vitamin K-rich foods."
Rationale: Warfarin is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent
clotting factors (II, VII, IX, and X). Its anticoagulant effect is monitored using the international
normalized ratio (INR). Fluctuations in dietary vitamin K intake can significantly alter the INR, leading
to either an increased risk of bleeding (if intake is decreased) or a loss of anticoagulant effect (if intake
is increased). Patients should be counseled to maintain a consistent daily intake of vitamin K-rich
foods, such as leafy green vegetables, rather than eliminating them entirely. Consistency is crucial for
stable anticoagulation. Avoiding vitamin K entirely could lead to an unstable INR and is not a
sustainable or safe long-term strategy.
5. A patient with type 2 diabetes mellitus is prescribed metformin. Which statement accurately
describes the primary mechanism of action of this medication?
A) It increases insulin secretion from pancreatic beta cells.
B) It decreases hepatic glucose production and improves insulin sensitivity.
C) It increases glucose absorption in the intestines.
D) It inhibits glucagon release from pancreatic alpha cells.
Correct Answer: It decreases hepatic glucose production and improves insulin sensitivity.
Rationale: Metformin is the first-line pharmacologic therapy for type 2 diabetes. Its primary
mechanism of action involves decreasing hepatic glucose production (gluconeogenesis) and improving
peripheral insulin sensitivity, which enhances glucose uptake by skeletal muscle and adipose tissue. It
does not directly stimulate insulin secretion, which is the mechanism of sulfonylureas and
meglitinides. It does not increase glucose absorption; in fact, it may decrease intestinal glucose
absorption. While it may have some effect on glucagon, this is not its primary mechanism.
Understanding this mechanism is essential for patient education and monitoring therapeutic
outcomes.
